Navigation Links
FDA Examines LASIK Surgery Complications
Date:4/28/2008

SHELBY TOWNSHIP, Michigan, April 28 /PRNewswire/ -- Nearly ten years after its arrival in the United States, and more than three years after FDA approval, LASIK surgery is coming under fire from some patients who have suffered complications or experienced poor outcomes.

Last Friday, the FDA heard testimony from patients who were dissatisfied with their LASIK surgery. Their complaints ranged from mild visual distortion, to pain, to severe activity-limiting visual halos and glare. One distraught parent read a suicide note from their child who described six years of eye pain and blurred vision.

The vast majority of patients have near perfect vision after LASIK surgery. In fact, the procedure has been quoted by many as having a 99% satisfaction rate. "My patients are, by and large, overjoyed with their results," stated Dr. William Goldstein, an ophthalmologist located in Shelby Township, Michigan. "Of course, like any surgery, LASIK has its downsides and patients need to be aware of the risks before they pursue this type of surgery."

Surgeons in the U.S. perform about 700,000 LASIK procedures every year, and the surgery is a popular means of reducing the need for glasses and contact lenses worldwide. But the limitations and risks of this surgery have lead many physicians to expand their practice to include other alternatives, such as Implantable Contact Lenses (ICL). Dr. Goldstein was the first in Michigan to perform this surgery, and has recommended it as an alternative to LASIK to many patients. "The Visian ICL offers the benefits of vision correction, while avoiding some of the problems that LASIK can cause," says Goldstein. "Patients who are not candidates for surgery due to dry eyes or extreme degrees of nearsightedness can feel secure that their most common complications are not an issue with this technology."

For more information, Dr. Goldstein can be reached at 586-323-2020. Visit his Web site at

SOURCE Dr. William Goldstein
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA Examines Quality of Life for LASIK Patients
2. Study examines the effect of epilepsy on the aging
3. Mayo Clinic Proceedings examines link between bacteria in the digestive system and obesity
4. Mayo Clinic Proceedings Examines a Possible Link Between Bacteria Found in the Human Digestive System and Obesity
5. Study examines how men and women view marital and parental time pressures
6. New U of C research examines commonly used toxin
7. Healthcare Tech and the World: Podcast Examines The Challenges & Opportunities for Change in the Healthcare Industry
8. Vet medicine researcher examines link between cancer, Down syndrome
9. Study examines self-expanding plastic stents in the treatment of benign esophageal conditions
10. Study examines decision-making deficits in older adults
11. LSU Forum Examines Health-Care Disparities and Access to Care
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 1GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 2GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 3GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 4GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 5GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 6nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 1nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 2MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2